<DOC>
	<DOCNO>NCT00496808</DOCNO>
	<brief_summary>Primary Objectives : - To determine effect single dose Herceptin ( trastuzumab ) proliferation rate Her-2/neu over-expressing ductal carcinoma situ ( DCIS ) - To evaluate effect single dose Herceptin apoptotic index Her-2/neu over-expressing DCIS</brief_summary>
	<brief_title>Neoadjuvant Herceptin Ductal Carcinoma In Situ Breast</brief_title>
	<detailed_description>Herceptin ( Trastuzumab ) stop slows growth certain breast cancer cell block chemical signal need grow . As part standard care DCIS , complete routine physical exam , mammogram breast , blood ( 2 tablespoon ) draw routine test . Some leftover breast biopsy tissue test Her-2/neu expression . Blood drawn ( 2-6 teaspoon ) check bone marrow ( red blood cell ) , kidney , liver function well enough treatment . Women able child must negative blood pregnancy test start treatment . If eligible take part study , receive one dose trastuzumab least 2 week surgery . The dose trastuzumab give intravenously ( needle vein arm ) steady infusion 90 minute , outpatient basis . You check infusion 1 hour complete . You routine surgery DCIS ( either segmental mastectomy , mastectomy without reconstruction , possible sentinel lymph node biopsy ) approximately 14 28 day give Herceptin . If segmental mastectomy perform part standard practice evaluate radiation oncologist follow surgery . After surgery , patient also evaluate breast medical oncologist determine additional standard therapy need . Tissue leave original breast biopsy surgery test various biomarkers ( substance indicate severity spread cancer ) , cancer growth rate , apoptotic index ( cell death rate ) . This investigational study . The FDA approve trastuzumab treatment breast cancer . Up 71 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . All patient histologic confirmation DCIS ( TisN0M0 ) Her2/neu 3+ positive immunohistochemistry ( IHC ) and/or positive Her2 gene amplification fluorescence situ hybridization ( FISH ) eligible study . 2 . Patients must sign informed consent indicate aware investigational nature study , keep institutional policy . 3 . Those patient history contralateral noninvasive invasive breast nonbreast malignancy eligible participate unless previously receive doxorubicin dose 400 mg/m2 . 4 . All patient adequate bone marrow function , define peripheral granulocyte count &gt; 1,500/mm3 , platelet count &gt; 100,000 mm3 . Patients must adequate liver function , bilirubin within normal laboratory value . In addition , patient adequate renal function , define serum creatinine &lt; 2.0 mg/dl . 5 . Patients intact primary tumor eligible study . Patients diagnostic biopsy outside facility still measurable disease presentation eligible . 6 . Patients history cardiac arrhythmia eligible study see cardiology deem good candidate participation . 7 . Women child bear potential must negative urine serum pregnancy test . 1 . Patients current know invasive breast cancer eligible study . 2 . All patient Her2/neu negative ineligible study . 3 . Patients history congestive heart failure exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Ductal Carcinoma In Situ</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>DCIS</keyword>
</DOC>